查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1594381

多發性硬化症市場：按治療方式、按應用分類 - 2025-2030 年全球預測

Multiple Sclerosis Market by Treatment Modality (Injectable Agents, Oral Agents), Application (Hospital, Research) - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年多發性硬化症市值為166.9億美元，預計到2024年將達到180.5億美元，複合年成長率為8.25%，預計到2030年將達到290.9億美元。

多發性硬化症 (MS) 是一種影響中樞神經系統的慢性自體免疫疾病，其症狀從輕微（如麻木）到嚴重（如癱瘓和視力喪失）不等。 MS 市場範圍包括旨在管理症狀和改變疾病進展的藥物、診斷和支持性護理技術。透過多發性硬化症治療來改善患者的生活品質和減緩疾病進展的需求已成為世界各地醫療保健系統不可或缺的一部分。治療方法包括干擾素等疾病修正治療、症狀治療和先進的診斷影像，最終用途主要在醫院、診所和居家醫療。市場成長受到診斷率上升、治療技術進步和老年人口增加的顯著影響。市場上的最新機會圍繞著個人化醫療、基因治療和新型單株抗體。建議投資研發並與生技公司建立策略聯盟，以抓住這些機會。然而，高昂的治療成本、複雜的醫藥品認證過程以及發展中地區的認知度低等挑戰正在阻礙成長。此外，市場參與企業還面臨學名藥和生物相似藥的競爭，利潤空間受到擠壓。成熟的創新領域包括用於早期診斷的生物標記開發、人工智慧驅動的患者管理系統以及具有成本效益的藥物製造流程，為業務成長提供了新的途徑。儘管該市場具有很高的成長潛力，但其性質意味著它受到嚴格的監管監督，並且在治療開發中必須考慮道德因素。為了克服這些挑戰，企業應專注於全球策略擴張，加強與研究機構的合作，並優先考慮以患者為中心的產品交付方法。注重教育和宣傳還可以幫助公司擴大市場範圍，並確保多發性硬化症治療在競爭激烈的環境中持續成長。

主要市場統計
基準年[2023] 166.9億美元
預測年份 [2024] 180.5億美元
預測年份 [2030] 290.9億美元
複合年成長率（%） 8.25%

市場動態：揭示快速發展的多發性硬化症市場的關鍵市場洞察

供需的動態交互作用正在改變多發性硬化症市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 對全球研發活動的大力投資
    • 政府支持提高公眾意識
    • 年輕人和老年人族群多發性硬化症的發生率不斷上升
  • 市場限制因素
    • 藥品價格相對較高
  • 市場機會
    • 對 Copaxone 和Tysabri等口服藥物的偏好日益增加
    • 主要企業新藥研發管線的出現
  • 市場挑戰
    • 嚴格的藥品核准監理政策

波特的五力：駕馭多發性硬化症市場的策略工具

波特的五力框架是理解市場競爭格局的重要工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點並避免潛在的挑戰，從而確保更強大的市場地位。

PESTLE分析：了解多發性硬化症市場的外部影響

外部宏觀環境因素在塑造多發性硬化症市場的績效動態方面發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析 了解多發性硬化症市場的競爭格局

對多發性硬化症市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣多發性硬化症市場供應商的績效評估

FPNV定位矩陣是評估多發性硬化症市場供應商的關鍵工具。此矩陣允許業務組織根據供應商的商務策略和產品滿意度評估供應商，從而做出符合其目標的明智決策。這四個象限使您能夠清晰、準確地分類供應商，以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議繪製多發性硬化症市場的成功之路

多發性硬化症市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機，並取得長期成功。

本報告對市場進行了全面分析，涵蓋關鍵重點領域：

1. 市場滲透率：對當前市場環境的詳細審查、主要企業的廣泛資料、對其在市場中的影響力和整體影響力的評估。

2. 市場開拓：辨識新興市場的成長機會，評估現有領域的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，幫助相關人員做出明智的決策：

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品、區隔市場和地區提供最佳投資機會？

3.塑造市場的主要技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 對全球研發活動的積極投資
      • 政府的有利支持以提高公眾意識
      • 年輕人和老年人多發性硬化症的發生率上升
    • 抑制因素
      • 藥品費用相對較高
    • 機會
      • Copaxone 和Tysabri等口服藥物越來越受到青睞。
      • 主要市場參與者新藥管道的出現
    • 任務
      • 嚴格的藥品核准監理政策
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章依治療方法的多發性硬化症市場

  • 注射
  • 口服劑

第7章 多發性硬化症市場：依應用分類

  • 醫院
  • 調查

第8章美洲多發性硬化症市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第9章亞太地區多發性硬化症市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第10章歐洲、中東和非洲多發性硬化症市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第11章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AbbVie Inc.
  • Allergan PLC
  • AstraZeneca PLC
  • Bayer AG
  • Biogen Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Merck & Co. Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Synthetic Biologics, Inc.
  • Teva Pharmaceuticals Industries Ltd.
Product Code: MRR-036C5CF3A89D

The Multiple Sclerosis Market was valued at USD 16.69 billion in 2023, expected to reach USD 18.05 billion in 2024, and is projected to grow at a CAGR of 8.25%, to USD 29.09 billion by 2030.

Multiple Sclerosis (MS) is a chronic autoimmune disorder affecting the central nervous system, characterized by symptoms ranging from mild, such as numbness, to severe, such as paralysis or loss of vision. The market scope for MS involves pharmaceuticals, diagnostics, and supportive care technologies aimed at managing symptoms and modifying disease progression. The necessity of MS treatments lies in improving patient quality of life and slowing disease progression, making them indispensable in healthcare systems worldwide. Applications include disease-modifying therapies like interferons, symptomatic treatments, and advanced imaging diagnostics, with primary end-use spanning hospitals, clinics, and home care settings. Market growth is heavily influenced by increased diagnosis rates, technological advancements in treatment, and a growing elderly population. The latest opportunities in the market revolve around personalized medicine, gene therapies, and novel monoclonal antibodies. To seize these opportunities, investment in R&D and strategic partnerships with biotech firms are recommended. However, challenges such as high treatment costs, complex drug approval processes, and limited awareness in developing regions hinder growth. Moreover, market players face competition from generic drugs and biosimilars, compressing profit margins. Areas ripe for innovation include biomarker development for early diagnosis, AI-driven patient management systems, and cost-effective drug manufacturing processes, offering new business growth avenues. Despite the robust growth potential, the market's nature is characterized by high regulatory scrutiny and ethical considerations in treatment developments. To navigate these challenges, firms should focus on global strategic expansion, enhance collaboration with research institutions, and prioritize patient-centric approaches in their product offerings. By emphasizing education and advocacy, companies can also broaden market reach and ensure sustained growth in the competitive landscape of MS treatments.

KEY MARKET STATISTICS
Base Year [2023] USD 16.69 billion
Estimated Year [2024] USD 18.05 billion
Forecast Year [2030] USD 29.09 billion
CAGR (%) 8.25%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Multiple Sclerosis Market

The Multiple Sclerosis Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Robust investment in research and development activities globally
    • Favorable government support to increase the awareness among people
    • Rising incidence of MS in young and elderly people
  • Market Restraints
    • Relatively high cost of the drugs
  • Market Opportunities
    • Increasing preference for oral drugs such as Copaxone and Tysabri
    • Emerging novel pipeline of drugs by key market players
  • Market Challenges
    • Stringent regulatory policies for drug approval

Porter's Five Forces: A Strategic Tool for Navigating the Multiple Sclerosis Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Multiple Sclerosis Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Multiple Sclerosis Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Multiple Sclerosis Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Multiple Sclerosis Market

A detailed market share analysis in the Multiple Sclerosis Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Multiple Sclerosis Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Multiple Sclerosis Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Multiple Sclerosis Market

A strategic analysis of the Multiple Sclerosis Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Multiple Sclerosis Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allergan PLC, AstraZeneca PLC, Bayer AG, Biogen Inc., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Mylan N.V., Novartis AG, Pfizer Inc., Sanofi S.A., Synthetic Biologics, Inc., and Teva Pharmaceuticals Industries Ltd..

Market Segmentation & Coverage

This research report categorizes the Multiple Sclerosis Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Treatment Modality, market is studied across Injectable Agents and Oral Agents.
  • Based on Application, market is studied across Hospital and Research.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Robust investment in research and development activities globally
      • 5.1.1.2. Favorable government support to increase the awareness among people
      • 5.1.1.3. Rising incidence of MS in young and elderly people
    • 5.1.2. Restraints
      • 5.1.2.1. Relatively high cost of the drugs
    • 5.1.3. Opportunities
      • 5.1.3.1. Increasing preference for oral drugs such as Copaxone and Tysabri
      • 5.1.3.2. Emerging novel pipeline of drugs by key market players
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory policies for drug approval
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Multiple Sclerosis Market, by Treatment Modality

  • 6.1. Introduction
  • 6.2. Injectable Agents
  • 6.3. Oral Agents

7. Multiple Sclerosis Market, by Application

  • 7.1. Introduction
  • 7.2. Hospital
  • 7.3. Research

8. Americas Multiple Sclerosis Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Multiple Sclerosis Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Multiple Sclerosis Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. Market Share Analysis, 2023
  • 11.2. FPNV Positioning Matrix, 2023
  • 11.3. Competitive Scenario Analysis
  • 11.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allergan PLC
  • 3. AstraZeneca PLC
  • 4. Bayer AG
  • 5. Biogen Inc.
  • 6. Eli Lilly and Company
  • 7. F. Hoffmann-La Roche AG
  • 8. GlaxoSmithKline PLC
  • 9. Merck & Co. Inc.
  • 10. Mylan N.V.
  • 11. Novartis AG
  • 12. Pfizer Inc.
  • 13. Sanofi S.A.
  • 14. Synthetic Biologics, Inc.
  • 15. Teva Pharmaceuticals Industries Ltd.

LIST OF FIGURES

  • FIGURE 1. MULTIPLE SCLEROSIS MARKET RESEARCH PROCESS
  • FIGURE 2. MULTIPLE SCLEROSIS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 11. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 13. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 19. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. MULTIPLE SCLEROSIS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. MULTIPLE SCLEROSIS MARKET DYNAMICS
  • TABLE 7. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY INJECTABLE AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL MULTIPLE SCLEROSIS MARKET SIZE, BY RESEARCH, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES MULTIPLE SCLEROSIS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY TREATMENT MODALITY, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM MULTIPLE SCLEROSIS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 99. MULTIPLE SCLEROSIS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 100. MULTIPLE SCLEROSIS MARKET, FPNV POSITIONING MATRIX, 2023